QQQ   314.61 (+0.60%)
AAPL   161.82 (+0.65%)
MSFT   282.38 (+0.67%)
META   206.34 (+0.48%)
GOOGL   100.69 (-0.69%)
AMZN   101.48 (+1.23%)
TSLA   195.88 (+1.03%)
NVDA   272.36 (+0.93%)
NIO   10.44 (+6.21%)
BABA   103.32 (+3.40%)
AMD   97.86 (+1.84%)
T   19.03 (+0.16%)
F   12.30 (+2.07%)
MU   62.88 (-1.04%)
CGC   1.77 (-2.49%)
GE   94.07 (+0.01%)
DIS   97.98 (+1.15%)
AMC   4.92 (-1.60%)
PFE   40.31 (+0.15%)
PYPL   74.23 (+0.07%)
NFLX   336.60 (+1.38%)
QQQ   314.61 (+0.60%)
AAPL   161.82 (+0.65%)
MSFT   282.38 (+0.67%)
META   206.34 (+0.48%)
GOOGL   100.69 (-0.69%)
AMZN   101.48 (+1.23%)
TSLA   195.88 (+1.03%)
NVDA   272.36 (+0.93%)
NIO   10.44 (+6.21%)
BABA   103.32 (+3.40%)
AMD   97.86 (+1.84%)
T   19.03 (+0.16%)
F   12.30 (+2.07%)
MU   62.88 (-1.04%)
CGC   1.77 (-2.49%)
GE   94.07 (+0.01%)
DIS   97.98 (+1.15%)
AMC   4.92 (-1.60%)
PFE   40.31 (+0.15%)
PYPL   74.23 (+0.07%)
NFLX   336.60 (+1.38%)
QQQ   314.61 (+0.60%)
AAPL   161.82 (+0.65%)
MSFT   282.38 (+0.67%)
META   206.34 (+0.48%)
GOOGL   100.69 (-0.69%)
AMZN   101.48 (+1.23%)
TSLA   195.88 (+1.03%)
NVDA   272.36 (+0.93%)
NIO   10.44 (+6.21%)
BABA   103.32 (+3.40%)
AMD   97.86 (+1.84%)
T   19.03 (+0.16%)
F   12.30 (+2.07%)
MU   62.88 (-1.04%)
CGC   1.77 (-2.49%)
GE   94.07 (+0.01%)
DIS   97.98 (+1.15%)
AMC   4.92 (-1.60%)
PFE   40.31 (+0.15%)
PYPL   74.23 (+0.07%)
NFLX   336.60 (+1.38%)
QQQ   314.61 (+0.60%)
AAPL   161.82 (+0.65%)
MSFT   282.38 (+0.67%)
META   206.34 (+0.48%)
GOOGL   100.69 (-0.69%)
AMZN   101.48 (+1.23%)
TSLA   195.88 (+1.03%)
NVDA   272.36 (+0.93%)
NIO   10.44 (+6.21%)
BABA   103.32 (+3.40%)
AMD   97.86 (+1.84%)
T   19.03 (+0.16%)
F   12.30 (+2.07%)
MU   62.88 (-1.04%)
CGC   1.77 (-2.49%)
GE   94.07 (+0.01%)
DIS   97.98 (+1.15%)
AMC   4.92 (-1.60%)
PFE   40.31 (+0.15%)
PYPL   74.23 (+0.07%)
NFLX   336.60 (+1.38%)
NASDAQ:HILS

Hillstream BioPharma - HILS Stock Forecast, Price & News

$0.84
-0.07 (-8.13%)
(As of 03/30/2023 02:10 PM ET)
Add
Compare
Today's Range
$0.82
$0.95
50-Day Range
$0.43
$1.89
52-Week Range
$0.30
$2.78
Volume
51,730 shs
Average Volume
3.21 million shs
Market Capitalization
$9.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Hillstream BioPharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Hillstream BioPharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.78) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

963rd out of 999 stocks

Pharmaceutical Preparations Industry

470th out of 489 stocks


HILS stock logo

About Hillstream BioPharma (NASDAQ:HILS) Stock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HILS Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Hillstream Nearly Doubles on Test Results
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Hillstream BioPharma, Inc. (HILS)
Hillstream BioPharma to Participate in the Fierce...
See More Headlines
Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HILS Company Calendar

Today
3/30/2023
Next Earnings (Estimated)
4/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HILS
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-8,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
6,897,000
Market Cap
$9.62 million
Optionable
Not Optionable
Beta
3.74

Key Executives

  • Mr. Randy D. Milby MBA (Age 69)
    Pres, Chairman & CEO
  • Mr. Thomas P. Hess CPA (Age 59)
    MBA, Chief Financial Officer













HILS Stock - Frequently Asked Questions

Should I buy or sell Hillstream BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HILS shares.
View HILS analyst ratings
or view top-rated stocks.

How have HILS shares performed in 2023?

Hillstream BioPharma's stock was trading at $0.3898 at the beginning of the year. Since then, HILS shares have increased by 114.5% and is now trading at $0.8360.
View the best growth stocks for 2023 here
.

Are investors shorting Hillstream BioPharma?

Hillstream BioPharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 116,100 shares, an increase of 25.1% from the February 28th total of 92,800 shares. Based on an average trading volume of 3,020,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 3.0% of the company's stock are short sold.
View Hillstream BioPharma's Short Interest
.

When is Hillstream BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 3rd 2023.
View our HILS earnings forecast
.

When did Hillstream BioPharma IPO?

(HILS) raised $21 million in an IPO on Wednesday, January 12th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share.

What is Hillstream BioPharma's stock symbol?

Hillstream BioPharma trades on the NASDAQ under the ticker symbol "HILS."

How do I buy shares of Hillstream BioPharma?

Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hillstream BioPharma's stock price today?

One share of HILS stock can currently be purchased for approximately $0.84.

How much money does Hillstream BioPharma make?

Hillstream BioPharma (NASDAQ:HILS) has a market capitalization of $9.62 million.

How can I contact Hillstream BioPharma?

The official website for the company is www.hillstreambio.com. The company can be reached via phone at 908-955-3140 or via email at investorrelations@hillstreambio.com.

This page (NASDAQ:HILS) was last updated on 3/30/2023 by MarketBeat.com Staff